title: Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
abstract: Proteasome inhibitors are emerging as a promising class of anti-cancer therapeutic agents. Bortezomib (PS341) is the first proteosome inhibitor with clinical significance. It acts by blocking vital functions of tumoral cells in myeloma, inducing apoptosis. Its toxicity is usually manageable. Gastrointestinal symptoms, peripheral neuropathy, neuropathic pain and thrombocytopenia are described as the most common side effects. We report on a case of cutaneous lesions induced by bortezomib in a patient with relapsed multiple myeloma (MM).
authors.affiliation: Department of Dermatology, Hospital Universitario de Canarias, University of La Laguna, La Laguna, Tenerife, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Rodríguez-Martín
authors.forename: M
authors.initials: M
authors.lastname: Sáez-Rodríguez
authors.forename: M
authors.initials: M
authors.lastname: García-Bustínduy
authors.forename: A
authors.initials: A
authors.lastname: Martín-Herrera
authors.forename: A
authors.initials: A
authors.lastname: Noda-Cabrera
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D011241:Prednisone / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D016879:Salvage Therapy; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D014750:Vincristine; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D011241:Prednisone